Free Trial

Pacira BioSciences (PCRX) Stock Price, News & Analysis

Pacira BioSciences logo
$25.84 +0.45 (+1.77%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$25.84 0.00 (0.00%)
As of 08/22/2025 06:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Pacira BioSciences Stock (NASDAQ:PCRX)

Key Stats

Today's Range
$25.23
$25.94
50-Day Range
$21.09
$25.84
52-Week Range
$12.61
$27.64
Volume
453,037 shs
Average Volume
830,081 shs
Market Capitalization
$1.16 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.83
Consensus Rating
Moderate Buy

Company Overview

Pacira BioSciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
68th Percentile Overall Score

PCRX MarketRank™: 

Pacira BioSciences scored higher than 68% of companies evaluated by MarketBeat, and ranked 330th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pacira BioSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Pacira BioSciences has only been the subject of 2 research reports in the past 90 days.

  • Read more about Pacira BioSciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Pacira BioSciences are expected to grow by 6.64% in the coming year, from $2.41 to $2.57 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pacira BioSciences is -9.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pacira BioSciences is -9.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pacira BioSciences has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Pacira BioSciences' valuation and earnings.
  • Percentage of Shares Shorted

    13.25% of the float of Pacira BioSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Pacira BioSciences has a short interest ratio ("days to cover") of 7.9.
  • Change versus previous month

    Short interest in Pacira BioSciences has recently increased by 4.21%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Pacira BioSciences does not currently pay a dividend.

  • Dividend Growth

    Pacira BioSciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.25% of the float of Pacira BioSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Pacira BioSciences has a short interest ratio ("days to cover") of 7.9.
  • Change versus previous month

    Short interest in Pacira BioSciences has recently increased by 4.21%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Pacira BioSciences has a news sentiment score of 1.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Pacira BioSciences this week, compared to 9 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added Pacira BioSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pacira BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $262,466.00 in company stock.

  • Percentage Held by Insiders

    Only 6.40% of the stock of Pacira BioSciences is held by insiders.

  • Percentage Held by Institutions

    99.73% of the stock of Pacira BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Pacira BioSciences' insider trading history.
Receive PCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter.

PCRX Stock News Headlines

Get This Stock Now
This company is the lifeblood of AI data centers, yet almost no one has caught up with the story. Their hardware is so essential that the data center industry uses enough of it to stretch around the world 8 times – in a single building! So, if you own Nvidia stock now, you might be well-served to sell those shares and check out this under-the-radar play instead. Or if you missed the boat on Nvidia, this is a rare second chance to target tremendous profit potential as AI data centers spring up in every corner of the world.tc pixel
Pacira reports Q2 EPS 74c, consensus 71c
Pacira (PCRX) Tops Q2 Earnings Estimates
See More Headlines

PCRX Stock Analysis - Frequently Asked Questions

Pacira BioSciences' stock was trading at $18.84 at the start of the year. Since then, PCRX shares have increased by 37.2% and is now trading at $25.84.

Pacira BioSciences, Inc. (NASDAQ:PCRX) posted its quarterly earnings results on Tuesday, August, 5th. The company reported $0.74 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.73 by $0.01. The company's revenue was up 1.7% on a year-over-year basis.
Read the conference call transcript
.

Top institutional shareholders of Pacira BioSciences include Balyasny Asset Management L.P. (4.74%), American Century Companies Inc. (2.63%), Geode Capital Management LLC (2.54%) and Assenagon Asset Management S.A. (1.04%). Insiders that own company stock include David M Stack, Daryl Gaugler, Frank D Lee, Kristen Williams, Jonathan Slonin, Lauren Riker, Roy Winston, Charles A Reinhart III, Max Reinhardt, Kristen Marie Williams, Lauren Bullaro Riker, Anthony Molloy, Mark A Kronenfeld, Mark Froimson and Marcelo Bigal.
View institutional ownership trends
.

Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pacira BioSciences investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
8/05/2025
Today
8/23/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:PCRX
CIK
1396814
Employees
720
Year Founded
2006

Price Target and Rating

High Price Target
$65.00
Low Price Target
$18.00
Potential Upside/Downside
+19.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.78)
Trailing P/E Ratio
N/A
Forward P/E Ratio
10.72
P/E Growth
N/A
Net Income
-$99.56 million
Net Margins
-18.08%
Pretax Margin
-15.11%
Return on Equity
13.29%
Return on Assets
6.61%

Debt

Debt-to-Equity Ratio
0.50
Current Ratio
2.38
Quick Ratio
1.91

Sales & Book Value

Annual Sales
$700.97 million
Price / Sales
1.66
Cash Flow
$4.39 per share
Price / Cash Flow
5.88
Book Value
$16.86 per share
Price / Book
1.53

Miscellaneous

Outstanding Shares
44,930,000
Free Float
42,057,000
Market Cap
$1.16 billion
Optionable
Optionable
Beta
0.48

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:PCRX) was last updated on 8/24/2025 by MarketBeat.com Staff
From Our Partners